Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery

Urothelial Cancer Clinical Trial

— PEGASUS  

Official title:

Open-label, Single-arm, Phase II Study, Evaluating Safety and Efficacy of INCB054828 (Pemigatinib) as Adjuvant Therapy for Molecularly-selected, High-risk Patients With Urothelial Carcinoma Who Have Received Radical Surgery

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04294277
• Other study ID #: EAU RF 2018-02
• Status: Terminated
• Phase: Phase 2
• Start date: July 13, 2020
• Est. completion date: November 15, 2022

Study information

• Verified date: February 2023
• Source: European Association of Urology Research Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to demonstrate the benefit of Pemigatinib, a drug that has indicated promising effects for relapse free survival in molecularly-selected, high-risk patients with urothelial carcinoma (UC) who have received radical surgery. Patients will receive Pemigatinib at a once-daily dose on a continuous schedule, continued until 12 months.

Description:

This is an open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma (UC) who have received radical surgery. Patients will receive Pemigatinib at a once-daily (QD) dose of 13.5 mg on a continuous schedule. Treatment will be continued until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.

Hyperphosphatemia can be managed with diet modification, phosphate binders, or dose modification. Since mineralization of the cornea and retinal changes consisting of serous retinal detachment have been reported in humans, ophthalmic exams are done at baseline and once every 12 weeks during treatment and should include a visual acuity test, slit-lamp examination and fundoscopy. Additional assessments (e.g. Orbital computerized tomography (CT) should be done if clinically relevant retinal findings are observed on ophthalmologic exams and in participants with reported visual adverse events (AEs) or change in visual acuity, if the events or changes are suspected to be of retinal origin.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: November 15, 2022
• Est. primary completion date: November 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological evidence of pT3-4 and/or pN1-3 UC of the urinary bladder or upper urinary tract after radical cystectomy / radical nephroureterectomy. Patients with mixed histologies are required to have a dominant (i.e. at least 50%) urothelial cell carcinoma pattern.

• Previous administration of at least 3 cycles of neoadjuvant cisplatin-based chemotherapy OR, if neoadjuvant chemotherapy was not administered, ineligibility to receive cisplatin-based adjuvant chemotherapy based on Galsky's criteria, that include at least one of the following: (1) WHO performance status = 2 and/or (2) creatinine-clearance < 60 ml/min and/or (3) CTCAE Gr = 2 hearing loss and/or (4) CTCAE Gr = 2 neuropathy.

• Evidence of FGFR alterations (mutations or translocations as specified in protocol) as assessed by a centralized Foundation Medicine test (Foundation One).

• Recovered with no evidence of disease confirmed by radiological images, prior to start of adjuvant therapy within 13 weeks after radical surgery.

• Willingness to avoid pregnancy or fathering children

• Written informed consent.

Exclusion Criteria:

• Any previous receipt of a selective FGFR inhibitor.

• Presence of primary CIS only.

• Presence of another malignancy in the 3 years before enrolment except for basal cell carcinoma or squamous cell carcinoma of the skin, cis of cervix, localised prostate cancer in active surveillance or other non invasive or other indolent malignancy that has undergone potentially curative therapy.

• Presence of pregnancy or lactation.

• Distant metastases (M1 disease).

• Treatment with other investigational drugs, receipt of anticancer medications (except for neoadjuvant cisplatin-based chemotherapy, see second inclusion criterion) or radiotherapy after radical surgery.

• Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half lives (whichever is longer) before the first dose of study treatment.

• Abnormal laboratory parameters:

• Total bilirubin = 1.5 × upper limit of normal (ULN; = 2.5 × ULN if Gilbert syndrome).

• AST and/or ALT > 2.5 × ULN

• Creatinine clearance = 30 mL/min based on Cockroft-Gault.

• Serum phosphate > institutional ULN.

• Serum calcium outside of the institutional normal range or serum albumin-corrected calcium outside of the institutional normal range when serum albumin is outside of the institutional normal range.

• History of human immunodeficiency virus infection or active tuberculosis infection.

• Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (exceeding > 10 mg daily of prednison equivalent; inhalation steroids are permitted).

• Evidence of hepatitis B virus or hepatitis C virus active infection or risk of reactivation.

• Severe hepatic impairment

• Known prior severe hypersensitivity to investigational products or its excipients

• History of clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months of enrolment, New York Heart Association Class III or IV.

• Current evidence of corneal disorder/keratopathy (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, etc) or retinal disorder (including but not limited to, central serous retinopathy, macular/retinal degeneration, diabetic retino-pathy, retinal detachment, etc) as confirmed by ophthalmologic examination.

• Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits.

Related Conditions & MeSH terms

• Urothelial Cancer

Intervention

Drug:
• Pemigatinib
At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.

Locations

Country	Name	City	State
Italy	ASST Papa Giovanni XXIII	Bergamo
Italy	Policlinico Sant'Orsola-Malpighi - Azienda Ospedaliero-Univeristaria di Bologna	Bologna
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milano
Italy	IRCCS San Raffaele Hospital	Milano
Italy	Fondazione Policlinico Universitario A. Gemelli, IRCCS	Roma

Sponsors (4)

Lead Sponsor	Collaborator
European Association of Urology Research Foundation	AMS Advanced Medical Services GmbH, High Research s.r.l., Incyte Biosciences International Sàrl

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relapse-free survival rate	Defined as the time from the date of start of study treatment until disease relapse or progression by Investigator determination, or death due to any cause, whichever occurs first.	Up to 2 years
Secondary	Overall Survival	Defined as the time from the date of start of study treatment to death due to any cause.	Up to 2 years
Secondary	Number of treatment-emergent adverse events [	Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.	Up to 2 years